Keynote-426: Pembrolizumab plus axitinib as a first-line treatment option for patients with advanced clear cell renal cell carcinoma

Prof. Thomas Powles

Director of Barts Cancer Centre, London, United Kingdom

In this episode, Prof. Powles discusses the results of the prespecified final analysis after 42 months of follow-up of the Keynote-426 trial, studying pembrolizumab plus axitinib versus sunitinib as a first-line treatment option for patients with advanced clear cell renal cell carcinoma.

Keynote-426: Pembrolizumab plus axitinib as a first-line treatment option for patients with advanced clear cell renal cell carcinoma
Prof. Thomas Powles
Director of Barts Cancer Centre, London, United Kingdom
In this episode, Prof. Powles discusses the results of the prespecified final analysis after 42 months of follow-up of the Keynote-426 trial, studying pembrolizumab plus axitinib versus sunitinib as a first-line treatment option for patients with advanced clear cell renal cell carcinoma.

Ariez Publishing Podcast

Ariez Publishing

PODCAST with prof. Thomas Powles about Keynote-426: Pembrolizumab plus axitinib as a first-line treatment option for patients with advanced clear cell renal cell carcinoma

Advertisement